Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John R Atack

Showing results (61-70 of 97) with videos related to

Pageof 10
Sort By:
Journal of Medicinal Chemistry|March 8, 2002
6,7-Dihydro-2-benzothiophen-4(5H)-ones: a novel class of GABA-A alpha5 receptor inverse agonistsMark S Chambers, John R Atack, Frances A Bromidge, et al.
EJNMMI Radiopharmacy and Chemistry|March 20, 2022
multi-patient dose synthesis of [18F]Flumazenil via a copper-mediated <sup>18</sup>F-fluorinationThibault Gendron, Gianluca Destro, Natan J W Straathof, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 25, 2016
Lipophilic nalmefene prodrugs to achieve a one-month sustained releaseTim Gaekens, Michel Guillaume, Herman Borghys, et al.
Journal of Medicinal Chemistry|October 7, 2022
Comparative Analysis of Small-Molecule LIMK1/2 Inhibitors: Chemical Synthesis, Biochemistry, and Cellular ActivityRoss Collins, Hyunah Lee, D Heulyn Jones, et al.
Bioorganic & Medicinal Chemistry Letters|November 24, 2005
Pharmacokinetics and metabolism studies on (3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy) pyrazolo[1,5-d][1,2,4]triazine, a functionally selective GABA(A) alpha5 inverse agonist for cognitive dysfunctionPhilip Jones, John R Atack, Matthew P Braun, et al.
Neuropharmacology|January 25, 2006
The in vivo properties of pagoclone in rat are most likely mediated by 5'-hydroxy pagocloneJohn R Atack, Andy Pike, George Marshall, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 4, 2018
Evidence That Sedative Effects of Benzodiazepines Involve Unexpected GABA<sub>A</sub> Receptor Subtypes: Quantitative Observation Studies in Rhesus MonkeysAngela N Duke, Zhiqiang Meng, Donna M Platt, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 14, 2006
The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouseJonathan D Best, David W Smith, Michael A Reilly, et al.
Bioorganic & Medicinal Chemistry Letters|August 2, 2011
The discovery and synthesis of JNJ 31020028, a small molecule antagonist of the Neuropeptide Y Y₂ receptorDevin M Swanson, Victoria D Wong, Jill A Jablonowski, et al.
Bioorganic & Medicinal Chemistry Letters|January 13, 2006
Imidazo[1,2-a]pyrimidines as functionally selective GABA(A) ligandsWesley P Blackaby, John R Atack, Frances Bromidge, et al.
Pageof 10

Showing results (61-70 of 97) with videos related to

Sort By:
Pageof 10
Journal of Medicinal Chemistry|March 8, 2002
6,7-Dihydro-2-benzothiophen-4(5H)-ones: a novel class of GABA-A alpha5 receptor inverse agonistsMark S Chambers, John R Atack, Frances A Bromidge, et al.
EJNMMI Radiopharmacy and Chemistry|March 20, 2022
multi-patient dose synthesis of [18F]Flumazenil via a copper-mediated <sup>18</sup>F-fluorinationThibault Gendron, Gianluca Destro, Natan J W Straathof, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 25, 2016
Lipophilic nalmefene prodrugs to achieve a one-month sustained releaseTim Gaekens, Michel Guillaume, Herman Borghys, et al.
Journal of Medicinal Chemistry|October 7, 2022
Comparative Analysis of Small-Molecule LIMK1/2 Inhibitors: Chemical Synthesis, Biochemistry, and Cellular ActivityRoss Collins, Hyunah Lee, D Heulyn Jones, et al.
Bioorganic & Medicinal Chemistry Letters|November 24, 2005
Pharmacokinetics and metabolism studies on (3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy) pyrazolo[1,5-d][1,2,4]triazine, a functionally selective GABA(A) alpha5 inverse agonist for cognitive dysfunctionPhilip Jones, John R Atack, Matthew P Braun, et al.
Neuropharmacology|January 25, 2006
The in vivo properties of pagoclone in rat are most likely mediated by 5'-hydroxy pagocloneJohn R Atack, Andy Pike, George Marshall, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 4, 2018
Evidence That Sedative Effects of Benzodiazepines Involve Unexpected GABA<sub>A</sub> Receptor Subtypes: Quantitative Observation Studies in Rhesus MonkeysAngela N Duke, Zhiqiang Meng, Donna M Platt, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 14, 2006
The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouseJonathan D Best, David W Smith, Michael A Reilly, et al.
Bioorganic & Medicinal Chemistry Letters|August 2, 2011
The discovery and synthesis of JNJ 31020028, a small molecule antagonist of the Neuropeptide Y Y₂ receptorDevin M Swanson, Victoria D Wong, Jill A Jablonowski, et al.
Bioorganic & Medicinal Chemistry Letters|January 13, 2006
Imidazo[1,2-a]pyrimidines as functionally selective GABA(A) ligandsWesley P Blackaby, John R Atack, Frances Bromidge, et al.
Pageof 10